OnKure Therapeutics, Inc.
OKUR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001637715
In the last 90 days, OnKure Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 75 institutions reported holding it in 13F filings for Q2 2026, worth $159.0M in total; no superinvestor holds it.
Holders of 5% or more of OKUR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of OnKure Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| AI Biotechnology LLC | 13D | 19.99%9.09M shares | New | Apr 7, 20261 filing | Apr 7, 2026 | SEC |
| Ra Capital Management, L.P. | 13G | 9.90%4.04M shares | New | Apr 7, 20261 filing | Apr 7, 2026 | SEC |
| Acorn Bioventures, L.P. | 13G | 9.50%3.92M shares | −12.60 ppfrom 22.10% | Oct 9, 20244 filings | Apr 1, 2026 | SEC |
| Biotechnology Value Fund L P | 13G/A | 8.00%3.24M shares | +2.70 ppfrom 5.30% | May 27, 20262 filings | Aug 14, 2026 | SEC |
| StepStone Group LP | 13G | 6.60%2.66M shares | New | Apr 7, 20261 filing | Apr 7, 2026 | SEC |
| Shay Capital LLC | 13G | 6.30%810.2K shares | New | May 29, 20251 filing | May 29, 2025 | SEC |
| ADAR1 Capital Management, LLC | 13G/A | 5.50%2.24M shares | −0.50 ppfrom 6.00% | Feb 17, 20263 filings | Aug 14, 2026 | SEC |
| Cantor Fitzgerald & Co. | 13G | 5.20%669.5K shares | New | Aug 14, 20251 filing | Aug 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
61 Schedule 13D and 13G filings on OnKure Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 30, 2023 | RiverVest Venture Fund III, L.P. | 13D/AOld format | – | – | – | SEC |
| May 15, 2023 | Novo Holdings A/S | 13D/AOld format | – | – | – | SEC |
| May 9, 20234:31 PM ET | Carlyle Group Inc. | 13D/AOld format | – | – | – | SEC |
| Sep 30, 2022 | Novo Holdings A/S | 13D/AOld format | – | – | – | SEC |
| Aug 11, 20224:52 PM ET | Carlyle Group Inc. | 13D/AOld format | – | – | – | SEC |
| Jan 27, 2022 | Novo Holdings A/S | 13D/AOld format | – | – | – | SEC |
| Jan 26, 2022 | Lundbeckfond Invest A/S | 13GOld format | – | New | – | SEC |
| Apr 23, 2021 | New Enterprise Associates 15, L.P. | 13DOld format | – | New | – | SEC |
| Apr 20, 2021 | Abingworth LLP | 13DOld format | – | New | – | SEC |
| Apr 19, 2021 | RiverVest Venture Fund III, L.P. | 13DOld format | – | New | – | SEC |
| Apr 14, 2021 | Novo Holdings A/S | 13DOld format | – | New | – | SEC |
Form 144: proposed insider sales
2 notices from officers, directors and other affiliates planning to sell OnKure Therapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Aug 28, 20235:33 PM ET | Hall AshleyOfficer | 15.6K | $98.1K | Aug 28, 2023 | ETRADE FINANCIAL CORPORATION | SEC |
| Jun 23, 20237:10 PM ET | Novo Holdings A/S10% stockholder | 100.0K | $735.0K | Jun 23, 2023 | Morgan Stanley & Co. LLC | SEC |